PMID- 32066680
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 2158-3188 (Electronic)
IS  - 2158-3188 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jan 21
TI  - Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in 
      medication-naive first-episode psychosis patients.
PG  - 15
LID - 10.1038/s41398-020-0700-6 [doi]
LID - 15
AB  - Antipsychotic medications are the cornerstone of treatment in schizophrenia 
      spectrum disorders. In first-episode psychosis, the recommended time for an 
      antipsychotic medication trial is up to 16 weeks, but the biological correlates 
      of shorter and longer antipsychotic treatment trials in these cohorts remain 
      largely unknown. We enrolled 29 medication-naive first-episode patients (FEP) and 
      22 matched healthy controls (HC) in this magnetic resonance spectroscopy (MRS) 
      study, examining the levels of combined glutamate and glutamine (commonly 
      referred to as Glx) in the bilateral medial prefrontal cortex (MPFC) with a PRESS 
      sequence (TR/TE = 2000/80 ms) before initiation of antipsychotic treatment, after 
      6 and 16 weeks of treatment with risperidone. Data were quantified in 18 HC and 
      20 FEP at baseline, for 19 HC and 15 FEP at week 6, and for 14 HC and 16 FEP at 
      week 16. At baseline, none of the metabolites differed between groups. Metabolite 
      levels did not change after 6 or 16 weeks of treatment in patients. Our data 
      suggest that metabolite levels do not change after 6 or 16 weeks of treatment 
      with risperidone in FEP. It is possible that our choice of sequence parameters 
      and the limited sample size contributed to negative findings reported here. On 
      the other hand, longer follow-up may be needed to detect treatment-related 
      metabolic changes with MRS. In summary, our study adds to the efforts in better 
      understanding glutamatergic neurometabolism in schizophrenia, especially as it 
      relates to antipsychotic exposure.
FAU - Birur, Badari
AU  - Birur B
AD  - Department of Psychiatry and Behavioral Neurobiology, University of Alabama at 
      Birmingham, Birmingham, AL, USA.
FAU - Kraguljac, Nina Vanessa
AU  - Kraguljac NV
AUID- ORCID: 0000-0003-2567-4098
AD  - Department of Psychiatry and Behavioral Neurobiology, University of Alabama at 
      Birmingham, Birmingham, AL, USA.
FAU - VerHoef, Lawrence
AU  - VerHoef L
AD  - Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, 
      USA.
FAU - Morgan, Charity J
AU  - Morgan CJ
AD  - Department of Psychiatry and Behavioral Neurobiology, University of Alabama at 
      Birmingham, Birmingham, AL, USA.
FAU - Jindal, Ripu Daman
AU  - Jindal RD
AD  - Department of Neurology, Birmingham VA Medical Center, Birmingham, AL, USA.
FAU - Reid, Meredith Amanda
AU  - Reid MA
AUID- ORCID: 0000-0003-1946-0544
AD  - MRI Research Center, Department of Electrical and Computer Engineering, Auburn 
      University, Auburn, AL, USA.
FAU - Luker, Austin
AU  - Luker A
AD  - Department of Psychiatry and Behavioral Neurobiology, University of Alabama at 
      Birmingham, Birmingham, AL, USA.
FAU - Lahti, Adrienne Carol
AU  - Lahti AC
AD  - Department of Psychiatry and Behavioral Neurobiology, University of Alabama at 
      Birmingham, Birmingham, AL, USA. alahti@uabmc.edu.
LA  - eng
GR  - K23 MH106683/MH/NIMH NIH HHS/United States
GR  - R01 MH081014/MH/NIMH NIH HHS/United States
GR  - R01 MH102951/MH/NIMH NIH HHS/United States
GR  - K23MH106683/U.S. Department of Health & Human Services | NIH | National 
      Institute of Mental Health (NIMH)/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200121
PL  - United States
TA  - Transl Psychiatry
JT  - Translational psychiatry
JID - 101562664
RN  - 0 (Antipsychotic Agents)
RN  - 3KX376GY7L (Glutamic Acid)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - *Antipsychotic Agents/therapeutic use
MH  - Glutamic Acid
MH  - Humans
MH  - *Psychotic Disorders/drug therapy
MH  - Risperidone/therapeutic use
MH  - *Schizophrenia/drug therapy
PMC - PMC7026447
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/02/19 06:00
MHDA- 2021/06/22 06:00
PMCR- 2020/01/21
CRDT- 2020/02/19 06:00
PHST- 2019/03/22 00:00 [received]
PHST- 2019/12/08 00:00 [accepted]
PHST- 2019/11/25 00:00 [revised]
PHST- 2020/02/19 06:00 [entrez]
PHST- 2020/02/19 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/01/21 00:00 [pmc-release]
AID - 10.1038/s41398-020-0700-6 [pii]
AID - 700 [pii]
AID - 10.1038/s41398-020-0700-6 [doi]
PST - epublish
SO  - Transl Psychiatry. 2020 Jan 21;10(1):15. doi: 10.1038/s41398-020-0700-6.